Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1970

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

Blood Adv (2025) 9 (15): 3865–3877.

https://doi.org/10.1182/bloodadvances.2024014903

Published: 2025

Includes: Supplemental data

Journal Articles

PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome

John M. Magenau, David G. Frame, Mary Riwes, John Maciejewski, Sarah Anand, Attaphol Pawarode, Anamarija M. Perry, Marcus Geer, Thomas Braun, Monalisa Ghosh, Pavan Reddy

Blood Adv (2025) 9 (15): 3878–3886.

https://doi.org/10.1182/bloodadvances.2024015200

Published: 2025

Includes: Supplemental data

Journal Articles

The CLUE postsurgery VTE risk instrument for abdominal and pelvic surgery: validation of patient risk factor component

Kari A. O. Tikkinen, Deborah M. Siegal, P. J. Devereaux, Sara V. Tornberg, Flavia K. Borges, Sandra Ofori, Jehonathan Pinthus, Bobby Shayegan, Lauri I. Lavikainen, Gordon H. Guyatt, Pavel S. Roshanov

Blood Adv (2025) 9 (15): 3837–3844.

https://doi.org/10.1182/bloodadvances.2024015515

Published: 2025

Journal Articles

ESCALATing care? Eltrombopag in pediatric aplastic anemia

Joshua Glass, Emma M. Groarke

Blood Adv (2025) 9 (15): 3819–3820.

https://doi.org/10.1182/bloodadvances.2025016872

Published: 2025

Journal Articles

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Thalia Padilla Kelley, Hannah King, Aditya Malhotra, Thomas G. DeLoughery, Kylee Martens, Joseph J. Shatzel

Blood Adv (2025) 9 (15): 3937–3945.

https://doi.org/10.1182/bloodadvances.2024015777

Published: 2025

Journal Articles

Targeting PD-1 for HCT relapse: an immunologic knife’s edge

Roman M. Shapiro, Robert J. Soiffer

Blood Adv (2025) 9 (15): 3907–3908.

https://doi.org/10.1182/bloodadvances.2025016709

Published: 2025

Journal Articles

Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease

Lana Mucalo Katunaric, Shuang Jia, Ashima Singh, Mark F. Roethle, Julie A. Panepinto, David C. Brousseau, Martin J. Hessner, Amanda M. Brandow

Blood Adv (2025) 9 (15): 3790–3800.

https://doi.org/10.1182/bloodadvances.2024015085

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O’Brien

Blood Adv (2025) 9 (15): 3801–3809.

https://doi.org/10.1182/bloodadvances.2024015417

Published: 2025

Journal Articles

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

Kellen Cristine Tjioe, Marisol Miranda-Galvis, Kenza Mamouni, Thalyta Freitas, Muhannad Sharara, Brenda Santellano, Claudia Guillén-Lopez, Jorge E. Cortes

Blood Adv (2025) 9 (15): 3810–3813.

https://doi.org/10.1182/bloodadvances.2024014340

Published: 2025

Includes: Supplemental data

Journal Articles

Use of the microfluidic impedance red cell assay in sickle cell disease

Akshay A. Patwardhan, Ashwin Patel, Abhinav Pasupuleti, Solomon Oshabaheebwa, Christopher A. Delianides, Zoe Sekyonda, Justin J. Yoo, Jonathan Wade, Erica Evans, Michael A. Suster, Pedram Mohseni, Umut A. Gurkan, Vivien A. Sheehan

Blood Adv (2025) 9 (15): 4004–4015.

https://doi.org/10.1182/bloodadvances.2024015590

Published: 2025

Includes: Supplemental data

Journal Articles

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

Blood Adv (2025) 9 (15): 3739–3749.

https://doi.org/10.1182/bloodadvances.2024015571

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Blood Adv (2025) 9 (15): 3665–3675.

https://doi.org/10.1182/bloodadvances.2024015180

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Adv (2025) 9 (15): 3694–3705.

https://doi.org/10.1182/bloodadvances.2024015262

Published: 2025

Includes: Supplemental data

Journal Articles

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results

Bruce D. Cheson, Nancy L. Bartlett, Betsy Knopf, Hun J. Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana A. Feldman, Stephen M. Ansell

Blood Adv (2025) 9 (15): 3750–3753.

https://doi.org/10.1182/bloodadvances.2025016470

Published: 2025

Journal Articles

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial

Blood Adv (2025) 9 (15): 3728–3738.

https://doi.org/10.1182/bloodadvances.2024015102

Published: 2025

Includes: Supplemental data

Journal Articles

NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine Diefenbach, Miguel-Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Yi Liu, PhD, Heng Xu, Christie Fanton, Sohail Chaudhry, Zachary Lee, A Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood Adv bloodadvances.2025016423.

https://doi.org/10.1182/bloodadvances.2025016423

Published: 2025

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS)

Ramya Ramaswami, Kathryn Lurain, Mark N Polizzotto, Anaida Widell, Irene Ekwede, Elena Tassi, Adam Rupert, Vickie Marshall, Mark Roth, Armando C Filie, Stefania Pittaluga, Elaine S Jaffe, Hao-Wei Wang, Denise Whitby, Thomas S Uldrick, Robert Yarchoan

Blood Adv bloodadvances.2025016685.

https://doi.org/10.1182/bloodadvances.2025016685

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Daratumumab in Immune Thrombocytopenia

Galina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, Dr, Henrik Frederiksen, Eirik Tjonnfjord, Ludvig A Munthe, Elsa Drivet, Hassen Kared, Ingvild Hausberg Sørvoll, Maria Therese Ahlen, Matthieu Mahevas, Marc Michel, James B. Bussel, David J Kuter, Tor Henrik Anderson Tvedt, Waleed Ghanima

Blood Adv bloodadvances.2025017279.

https://doi.org/10.1182/bloodadvances.2025017279

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic Impact of the PredicT-ALL Classifier in the AALL0434 Trial: A Model Combining NGS, MRD and WBC at Diagnosis

Mathieu Simonin, Nicolas Boissel, Arnaud Petit, Charles G. Mullighan, Stephen P Hunger, Mignon L. Loh, Stuart Sheldon Winter, Elizabeth A. Macintyre, David Trent Teachey, André BARUCHEL, Vahid Asnafi

Blood Adv bloodadvances.2025017399.

https://doi.org/10.1182/bloodadvances.2025017399

Published: 2025

Includes: Supplemental data

Journal Articles

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

Jong Wook Lee, Jun Ho Jang, Hirohito Yamazaki, Masashi Sawa, Masahiro Kizaki, Yoshiaki Tomiyama, Koji Nagafuji, Kensuke Usuki, Jyh-Pyng Gau, Yasuyoshi Morita, Jih-Luh Tang, Hung Chang, Masayoshi Noshiro, Akira Matsuda, Keiya Ozawa, Kinuko Mitani, Yoshinobu Kanda, Shinji Nakao

Blood Adv bloodadvances.2024014855.

https://doi.org/10.1182/bloodadvances.2024014855

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome

The CLUE postsurgery VTE risk instrument for abdominal and pelvic surgery: validation of patient risk factor component

ESCALATing care? Eltrombopag in pediatric aplastic anemia

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Targeting PD-1 for HCT relapse: an immunologic knife’s edge

Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

Use of the microfluidic impedance red cell assay in sickle cell disease

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial

NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma

Characteristics and outcomes of Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS)

Safety and Efficacy of Daratumumab in Immune Thrombocytopenia

Prognostic Impact of the PredicT-ALL Classifier in the AALL0434 Trial: A Model Combining NGS, MRD and WBC at Diagnosis

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only